Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
XTLB
XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd ADR (XTLB) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.4
/ 5.0
C
Value
C+
Factor Score
2.7
/ 5.0
Growth
C-
Factor Score
2.0
/ 5.0
Profitability
C+
Factor Score
2.7
/ 5.0
Momentum
C
Factor Score
2.4
/ 5.0
Revisions
C-
Factor Score
2.0
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
0.0
EV / EBITDA
16.9
Rev Growth YoY
0.0%
Gross Margin
N/M
Price Return 3M
-27.7%
Price Return 12M
-58.5%
Catalyst Signal
0.00
Market Cap
N/A
TTM Revenue
N/A
Price / Sales
5.8
ROE
-29.3%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-03 | C+ (2.7) | C- (2.0) | C+ (2.7) | C (2.4) | C- (2.0) | C (2.4) |